Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,371,601 papers from all fields of science
Search
Sign In
Create Free Account
arzoxifene
A synthetic, aromatic derivative with anti-estrogenic properties. Similar to the agent raloxifene, arzoxifene binds to and interacts with estrogen…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
LY 353381
arzoxifene hydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Prevention: Targeted therapy—anastrozole prevents breast cancer
P. Brown
Nature Reviews Clinical Oncology
2014
Corpus ID: 32608358
The recent IBIS-II clinical trial results demonstrate anastrozole reduces breast cancer incidence by 53% in postmenopausal women…
Expand
Review
2013
Review
2013
Breast cancer prevention by antihormones and other drugs: where do we stand?
M. Lazzeroni
,
A. Decensi
Hematology/Oncology Clinics of North America
2013
Corpus ID: 205115747
2012
2012
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene
T. J. Powles
,
S. Diem
,
+8 authors
Steven R. Cummings
Breast Cancer Research and Treatment
2012
Corpus ID: 23117278
The Generations trial, a multicenter, placebo-controlled, double-blind trial, compared arzoxifene 20 mg/day and placebo in 9,354…
Expand
2012
2012
Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass
S. Goldstein
,
H. Bhattoa
,
+5 authors
D. Muram
Menopause
2012
Corpus ID: 27588692
ObjectiveThe aim of this study was to report the gynecologic safety findings from the Generations trial, a phase 3 study of the…
Expand
2006
2006
Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene.
C. Fabian
,
B. Kimler
,
+7 authors
D. Browne
Journal of Clinical Oncology
2006
Corpus ID: 21052931
1001 Background: Arzoxifene (ARZ) is a third generation SERM with efficacy in metastatic breast cancer but lacking uterine…
Expand
2005
2005
Effect of the Selective Estrogen Receptor Modulator Arzoxifene on Repopulation of Hormone-Responsive Breast Cancer Xenografts between Courses of Chemotherapy
Licun Wu
,
I. Tannock
Clinical Cancer Research
2005
Corpus ID: 7325413
Selective inhibition of repopulation of clonogenic tumor cells between courses of chemotherapy has potential to improve the…
Expand
Review
2004
Review
2004
Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
A. Gadducci
,
S. Cosio
,
A. Genazzani
Current opinion in investigational drugs
2004
Corpus ID: 44895581
The new anti-estrogens, including the selective estrogen receptor modulators (e.g., toremifene, droloxifene, idoxifene…
Expand
Review
2003
Review
2003
Novel therapies for osteoporosis
D. Biskobing
Expert Opinion on Investigational Drugs
2003
Corpus ID: 20675062
Osteoporosis remains a significant clinical problem despite effective therapies. Many patients cannot or will not take currently…
Expand
Review
2002
Review
2002
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
S. Chan
Seminars in Oncology
2002
Corpus ID: 19813833
Highly Cited
2001
Highly Cited
2001
Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
J. M. Schafer
,
E. Lee
,
+4 authors
V. Jordan
Clinical Cancer Research
2001
Corpus ID: 5821590
PURPOSE Cross-resistance is the primary issue facing the evaluation of new antiestrogens to treat metastatic breast cancer…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE